Search
Sodium bisulfite
go.drugbank.com/drugs/DB14015ApprovedWithdrawnSodium bisulfite has been used externally for parasitic skin diseases and as a gastrointestinal antiseptic.
Categories: Compounds used in a research, industrial, or household settingCoccidioides immitis spherule
go.drugbank.com/drugs/DB11294ApprovedCoccidioides immitis spherule is a skin test antigen indicated to detect delayed-type hypersensitivity to Coccidioides immitis in individuals with a history of pulmonary coccidioidomycosis.
Vonicog alfa
go.drugbank.com/drugs/DB12872ApprovedInvestigational[A264389] Vonicog alfa works to reduce bleeding events and bleeding times in patients with vWD, who have deficiencies in VWF.[A264389] … [A264444] Used to treat von Willebrand Disease (vWD), it mimics the biological actions of endogenous VWF,[L51274] which is a critical plasma glycoprotein involved in platelet adhesion and aggregation.
Aminohippuric acid
go.drugbank.com/drugs/DB00345ApprovedInvestigationalWithdrawnThe glycine amide of 4-aminobenzoic acid. Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity. [PubChem]
Synonyms: N-(p-Aminobenzoyl)glycine, N-(para-aminobenzoyl)glycineCategories: Compounds used in a research, industrial, or household settingMetixene
go.drugbank.com/drugs/DB00340ApprovedMetixene (or methixene) is a anticholinergic used as an antiparkinsonian agent.
Dofetilide
go.drugbank.com/drugs/DB00204ApprovedInvestigationalDofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation
Zalcitabine
go.drugbank.com/drugs/DB00943ApprovedWithdrawnA dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen. … Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.
Elosulfase alfa
go.drugbank.com/drugs/DB09051ApprovedInvestigationalElosulfase alfa is a synthetic version of the enzyme N-acetylgalactosamine-6-sulfatase. It was approved by the FDA in 2014 for the treatment of Morquio syndrome. … The recommended dose is 2 mg per kg given intravenously over a minimum range of 3.5 to 4.5 hours, based on infusion volume, once every week.
Synonyms: Recombinant human N-acetylgalactosamine-6-sulfatase, Recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS)Tioguanine
go.drugbank.com/drugs/DB00352ApprovedInvestigationalAn antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.